Ovid Therapeutics Inc. (OVID) 10-Year Financial Performance & Capital Metrics

OVID • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutOvid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Show more

Revenue $566K +44.4%
EBITDA -$61M -4.4%
Net Income -$26M +49.5%
EPS (Diluted) -0.37 +50.0%
Gross Margin 100%
EBITDA Margin -10825.44% +27.7%
Operating Margin -10933.75% +27.7%
Net Margin -4670.14% +65.0%
ROE -33.88% +28.8%
ROIC -69.57% -41.4%
Debt/Equity 0.22 +18.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-86.05%

TTM945.89%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-11.78%

EPS CAGR

10Y-

5Y-

3Y-

TTM-7.64%

ROCE

10Y Avg-53.04%

5Y Avg-31.74%

3Y Avg-44.62%

Latest-57.78%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.54B	26.86	19.75	31.85%	24.94%	28.47%	3.46%	0.07
JAZZJazz Pharmaceuticals plc	10.38B	170.81	19.75	6.12%	-8.86%	-9.31%	12.99%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.85B	23.17	17.69	23.49%	37.63%	23.64%	8.4%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.08B	36.04	14.36	22.8%	22.48%	22.23%	10.53%	0.28
ALKSAlkermes plc	5.06B	30.62	14.11	-6.36%	22.27%	19.55%	8.02%	0.05
PRTCPureTech Health plc	458.47M	18.97	9.49	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	489.79M	19.36	-1.09
NMRANeumora Therapeutics, Inc. Common Stock	365.37M	2.15	-1.41			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	12.62M	208.38M	1.5M	392K	566K
Revenue Growth %	-	-	-	-	-	-	15.52%	-0.99%	-0.74%	0.44%
Cost of Goods Sold+	11.78K	0	80.31K	141.73K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-11.78K	-56.51K	-80.31K	-142K	0	12.62M	208.38M	1.5M	392K	566K
Gross Margin %	-	-	-	-	-	1%	1%	1%	1%	1%
Gross Profit Growth %	-	-3.8%	-0.42%	-0.77%	1%	-	15.52%	-0.99%	-0.74%	0.44%
Operating Expenses+	13.19M	22.54M	65.01M	52.93M	61.41M	94.05M	84.17M	57.05M	59.67M	62.45M
OpEx % of Revenue	-	-	-	-	-	7.45%	0.4%	37.96%	152.23%	110.34%
Selling, General & Admin	6.58M	12.95M	15.04M	19.14M	19.25M	30.63M	37.23M	32.43M	29.59M	25.68M
SG&A % of Revenue	-	-	-	-	-	2.43%	0.18%	21.58%	75.47%	45.38%
Research & Development	6.61M	9.59M	49.97M	33.79M	46.86M	64.12M	46.94M	24.62M	28.59M	36.77M
R&D % of Revenue	-	-	-	-	-	5.08%	0.23%	16.38%	72.93%	64.96%
Other Operating Expenses	0	0	0	0	-4.7M	-700K	1.1K	510	1.5M	1K
Operating Income+	-13.19M	-22.54M	-65.01M	-52.93M	-61.41M	-81.43M	124.21M	-55.55M	-59.28M	-61.88M
Operating Margin %	-	-	-	-	-	-6.45%	0.6%	-36.96%	-151.23%	-109.34%
Operating Income Growth %	-28.51%	-0.71%	-1.88%	0.19%	-0.16%	-0.33%	2.53%	-1.45%	-0.07%	-0.04%
EBITDA+	-13.18M	-22.48M	-64.93M	-52.79M	-61.15M	-81.12M	124.45M	-54.17M	-58.71M	-61.27M
EBITDA Margin %	-	-	-	-	-	-6.43%	0.6%	-36.05%	-149.78%	-108.25%
EBITDA Growth %	-28.63%	-0.71%	-1.89%	0.19%	-0.16%	-0.33%	2.53%	-1.44%	-0.08%	-0.04%
D&A (Non-Cash Add-back)	11.78K	56.51K	80.31K	141.73K	255K	306.85K	237.08K	1.38M	568K	613K
EBIT	-13.19M	-22.54M	-64.81M	-52.93M	-61.41M	-81.43M	124.21M	-55.55M	-57.58M	-58.38M
Net Interest Income+	0	0	0	0	948.22K	395.4K	0	0	4.9M	3.9M
Interest Income	30.28K	0	201.51K	952.07K	948.22K	395.4K	0	0	4.9M	3.9M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	30.28K	120.82K	201.51K	952.07K	948.22K	395.4K	-45.69K	1.38M	6.94M	35.45M
Pretax Income+	-13.16M	-22.41M	-64.81M	-51.98M	-60.46M	-81.04M	124.16M	-54.17M	-52.34M	-26.43M
Pretax Margin %	-	-	-	-	-	-6.42%	0.6%	-36.05%	-133.52%	-46.7%
Income Tax+	0	-950	-80.31K	0	0	0	1.33M	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	0.99%	1%	1%	1%
Net Income+	-13.16M	-22.41M	-64.81M	-51.98M	-60.46M	-81.04M	122.83M	-54.17M	-52.34M	-26.43M
Net Margin %	-	-	-	-	-	-6.42%	0.59%	-36.05%	-133.52%	-46.7%
Net Income Growth %	-28.44%	-0.7%	-1.89%	0.2%	-0.16%	-0.34%	2.52%	-1.44%	0.03%	0.49%
Net Income (Continuing)	-13.16M	-22.41M	-64.81M	-51.98M	-60.46M	-81.04M	122.83M	-54.17M	-52.34M	-26.43M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.67	-1.14	-3.35	-2.11	-1.51	-1.39	1.76	-0.77	-0.74	-0.37
EPS Growth %	-6.13%	-0.7%	-1.94%	0.37%	0.28%	0.08%	2.27%	-1.44%	0.04%	0.5%
EPS (Basic)	-0.67	-1.14	-3.35	-2.11	-1.51	-1.39	1.78	-0.77	-0.74	-0.37
Diluted Shares Outstanding	19.6M	19.6M	19.34M	24.63M	39.22M	58.45M	68.07M	70.42M	70.58M	70.91M
Basic Shares Outstanding	19.6M	19.6M	19.34M	24.63M	39.22M	58.45M	67.48M	70.42M	70.58M	70.91M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	70.28M	52.41M	88.59M	44.27M	79.81M	74.84M	190.48M	131.38M	109.6M	55.94M
Cash & Short-Term Investments	69.94M	51.94M	87.13M	41.5M	76.74M	72.03M	187.8M	129M	105.83M	53.08M
Cash Only	69.94M	51.94M	87.13M	36.49M	41.9M	72.03M	187.8M	44.87M	27.04M	26.3M
Short-Term Investments	0	0	0	5.01M	34.84M	0	0	84.13M	78.79M	26.77M
Accounts Receivable	0	7.37K	0	0	1.13M	141.76K	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	4.1	-	-	-	-
Inventory	0	242.67K	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	58.64K	242.67K	0	600.1K	0	0	2.68M	1	1K	0
Total Non-Current Assets+	93.26K	616.68K	869.55K	3.38M	1.03M	1.08M	4.07M	23.89M	34.43M	36.23M
Property, Plant & Equipment	29.52K	43.59K	51.77K	69.87K	68.36K	135.62K	242.76K	16.07M	14.66M	13.23M
Fixed Asset Turnover	-	-	-	-	-	93.03x	858.40x	0.09x	0.03x	0.04x
Goodwill	0	0	0	0	-247	100	0	0	0	0
Intangible Assets	18.89K	110.07K	124.19K	391.87K	467.25K	318.9K	164K	222.1K	200K	92K
Long-Term Investments	0	0	0	0	0	0	3.56M	5.62M	17.63M	20.97M
Other Non-Current Assets	44.85K	463.01K	693.59K	2.92M	495.18K	627.8K	96.13K	1.97M	1.94M	1.93M
Total Assets+	70.38M	53.03M	89.46M	47.65M	80.84M	75.93M	194.54M	155.27M	144.03M	92.17M
Asset Turnover	-	-	-	-	-	0.17x	1.07x	0.01x	0.00x	0.01x
Asset Growth %	13.49%	-0.25%	0.69%	-0.47%	0.7%	-0.06%	1.56%	-0.2%	-0.07%	-0.36%
Total Current Liabilities+	2.31M	3.73M	6.02M	8.84M	10.53M	22.06M	14.8M	6.99M	11.47M	10.52M
Accounts Payable	670.54K	857.17K	2.03M	3.76M	3.26M	5.45M	7.13M	1.95M	3.7M	3.19M
Days Payables Outstanding	20.78K	-	9.21K	9.67K	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	1000K	0	0	0	0
Other Current Liabilities	0	0	2.08M	2.31M	4.55M	8.19M	3.91M	0	0	1K
Current Ratio	30.44x	14.04x	14.71x	5.01x	7.58x	3.39x	12.87x	18.79x	9.55x	5.32x
Quick Ratio	30.44x	13.97x	14.71x	5.01x	7.58x	3.39x	12.87x	18.79x	9.55x	5.32x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	286.56K	10.23M	0	16M	44.76M	13.42M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	16M	14.76M	13.42M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	286.56K	61.2K	0	1	30M	0
Total Liabilities	2.31M	3.73M	6.02M	8.84M	10.82M	32.29M	14.8M	22.99M	56.23M	23.94M
Total Debt+	0	0	0	0	0	0	0	16.54M	16M	14.76M
Net Debt	-69.94M	-51.94M	-87.13M	-36.49M	-41.9M	-72.03M	-187.8M	-28.33M	-11.04M	-11.55M
Debt / Equity	-	-	-	-	-	-	-	0.13x	0.18x	0.22x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-1.51x	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	68.07M	49.29M	83.44M	38.81M	70.02M	43.63M	179.75M	132.27M	87.8M	68.23M
Equity Growth %	13.37%	-0.28%	0.69%	-0.53%	0.8%	-0.38%	3.12%	-0.26%	-0.34%	-0.22%
Book Value per Share	3.47	2.51	4.31	1.58	1.79	0.75	2.64	1.88	1.24	0.96
Total Shareholders' Equity	68.07M	49.29M	83.44M	38.81M	70.02M	43.63M	179.75M	132.27M	87.8M	68.23M
Common Stock	21.15K	19.6K	24.61K	24.65K	54.71K	65.74K	70.36K	70.47K	71K	71K
Retained Earnings	-13.5M	-61.77M	-100.72M	-152.7M	-213.16M	-294.19M	-171.36M	-225.53M	-277.87M	-304.3M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-20.19K	-50.91K	-1.83K	2.47K	0	0	-42.19K	0	-35K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.49M	-17.8M	-31.47M	-45.56M	-51.09M	-51.58M	118.61M	-55.23M	-45.78M	-55.96M
Operating CF Margin %	-	-	-	-	-	-4.09%	0.57%	-36.75%	-116.79%	-98.86%
Operating CF Growth %	-19.99%	-2.25%	-0.77%	-0.45%	-0.12%	-0.01%	3.3%	-1.47%	0.17%	-0.22%
Net Income	-13.16M	-22.41M	-64.81M	-51.98M	-60.46M	-81.04M	119.84M	-54.17M	-52.34M	-26.43M
Depreciation & Amortization	11.78K	56.51K	80.31K	141.73K	255K	306.85K	237K	1.38M	1.6M	613K
Stock-Based Compensation	1.46M	3.64M	6.4M	7.06M	5.21M	7.53M	0	6.56M	7.29M	6.28M
Deferred Taxes	0	-3.64M	0	4.61K	0	0	0	0	0	0
Other Non-Cash Items	4.39M	3.64M	25.86M	-1.24K	-29.63K	-199.41K	15.35M	-764.94K	-4.71M	-36.26M
Working Capital Changes	1.81M	914.4K	996.85K	-787.91K	3.94M	21.82M	-16.81M	-8.23M	2.39M	-150K
Change in Receivables	-69.22K	50.26K	7.37K	0	-531.04K	989.38K	141.76K	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	591.41K	186.62K	1.08M	1.65M	-653.95K	2.33M	1.7M	-5.17M	1.75M	-512K
Cash from Investing+	-56.33K	-188.99K	-47.39K	-5.36M	-30.04M	34.65M	-1.82M	-87.88M	-2.58M	54.59M
Capital Expenditures	-56.33K	-188.99K	-47.39K	-352.02K	-57.16K	-127.24K	-189.41K	-1.42M	-40.31K	-71K
CapEx % of Revenue	-	-	-	-	-	0.01%	0%	0.94%	0.1%	0.13%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-24.25K	-158.62K	-8.48K	-318.15K	-186.89K	-263.44K	0	-1M	-97.15K	-89K
Cash from Financing+	70.64M	-13.67K	66.7M	286.14K	86.54M	47.07M	904.08K	180.66K	30.54M	622K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-13.67K	-3.05M	286.14K	131.9K	341.04K	-21.31K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.54M	-17.99M	-31.52M	-45.91M	-51.33M	-51.97M	118.43M	-56.65M	-45.92M	-56.03M
FCF Margin %	-	-	-	-	-	-4.12%	0.57%	-37.69%	-117.14%	-98.99%
FCF Growth %	-20.07%	-2.25%	-0.75%	-0.46%	-0.12%	-0.01%	3.28%	-1.48%	0.19%	-0.22%
FCF per Share	-0.28	-0.92	-1.63	-1.86	-1.31	-0.89	1.74	-0.80	-0.65	-0.79
FCF Conversion (FCF/Net Income)	0.42x	0.79x	0.49x	0.88x	0.85x	0.64x	0.97x	1.02x	0.87x	2.12x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-36.15%	-38.2%	-97.65%	-85.04%	-111.11%	-142.6%	109.98%	-34.72%	-47.57%	-33.88%
Return on Invested Capital (ROIC)	-	-	-	-	-302.59%	-	-	-86.89%	-49.21%	-69.57%
Gross Margin	-	-	-	-	-	100%	100%	100%	100%	100%
Net Margin	-	-	-	-	-	-642.26%	58.95%	-3604.66%	-13351.79%	-4670.14%
Debt / Equity	-	-	-	-	-	-	-	0.13x	0.18x	0.22x
FCF Conversion	0.42x	0.79x	0.49x	0.88x	0.85x	0.64x	0.97x	1.02x	0.87x	2.12x
Revenue Growth	-	-	-	-	-	-	1551.57%	-99.28%	-73.91%	44.39%

Revenue by Segment

	2021	2022
License	12.38M	1.5M
License Growth	-	-87.86%
Related Party	196M	-
Related Party Growth	-	-

Frequently Asked Questions

Growth & Financials

Ovid Therapeutics Inc. (OVID) reported $6.6M in revenue for fiscal year 2024.

Ovid Therapeutics Inc. (OVID) grew revenue by 44.4% over the past year. This is strong growth.

Ovid Therapeutics Inc. (OVID) reported a net loss of $36.3M for fiscal year 2024.

Dividend & Returns

Ovid Therapeutics Inc. (OVID) has a return on equity (ROE) of -33.9%. Negative ROE indicates the company is unprofitable.

Ovid Therapeutics Inc. (OVID) had negative free cash flow of $38.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Ovid Therapeutics Inc. (OVID) 10-Year Financial Performance & Capital Metrics

OVID • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $566K +44.4%
EBITDA -$61M -4.4%
Net Income -$26M +49.5%
EPS (Diluted) -0.37 +50.0%
Gross Margin 100%
EBITDA Margin -10825.44% +27.7%
Operating Margin -10933.75% +27.7%
Net Margin -4670.14% +65.0%
ROE -33.88% +28.8%
ROIC -69.57% -41.4%
Debt/Equity 0.22 +18.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-86.05%

TTM945.89%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-11.78%

EPS CAGR

10Y-

5Y-

3Y-

TTM-7.64%

ROCE

10Y Avg-53.04%

5Y Avg-31.74%

3Y Avg-44.62%

Latest-57.78%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.54B	26.86	19.75	31.85%	24.94%	28.47%	3.46%	0.07
JAZZJazz Pharmaceuticals plc	10.38B	170.81	19.75	6.12%	-8.86%	-9.31%	12.99%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.85B	23.17	17.69	23.49%	37.63%	23.64%	8.4%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.08B	36.04	14.36	22.8%	22.48%	22.23%	10.53%	0.28
ALKSAlkermes plc	5.06B	30.62	14.11	-6.36%	22.27%	19.55%	8.02%	0.05
PRTCPureTech Health plc	458.47M	18.97	9.49	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	489.79M	19.36	-1.09
NMRANeumora Therapeutics, Inc. Common Stock	365.37M	2.15	-1.41			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	12.62M	208.38M	1.5M	392K	566K
Revenue Growth %	-	-	-	-	-	-	15.52%	-0.99%	-0.74%	0.44%
Cost of Goods Sold+	11.78K	0	80.31K	141.73K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-11.78K	-56.51K	-80.31K	-142K	0	12.62M	208.38M	1.5M	392K	566K
Gross Margin %	-	-	-	-	-	1%	1%	1%	1%	1%
Gross Profit Growth %	-	-3.8%	-0.42%	-0.77%	1%	-	15.52%	-0.99%	-0.74%	0.44%
Operating Expenses+	13.19M	22.54M	65.01M	52.93M	61.41M	94.05M	84.17M	57.05M	59.67M	62.45M
OpEx % of Revenue	-	-	-	-	-	7.45%	0.4%	37.96%	152.23%	110.34%
Selling, General & Admin	6.58M	12.95M	15.04M	19.14M	19.25M	30.63M	37.23M	32.43M	29.59M	25.68M
SG&A % of Revenue	-	-	-	-	-	2.43%	0.18%	21.58%	75.47%	45.38%
Research & Development	6.61M	9.59M	49.97M	33.79M	46.86M	64.12M	46.94M	24.62M	28.59M	36.77M
R&D % of Revenue	-	-	-	-	-	5.08%	0.23%	16.38%	72.93%	64.96%
Other Operating Expenses	0	0	0	0	-4.7M	-700K	1.1K	510	1.5M	1K
Operating Income+	-13.19M	-22.54M	-65.01M	-52.93M	-61.41M	-81.43M	124.21M	-55.55M	-59.28M	-61.88M
Operating Margin %	-	-	-	-	-	-6.45%	0.6%	-36.96%	-151.23%	-109.34%
Operating Income Growth %	-28.51%	-0.71%	-1.88%	0.19%	-0.16%	-0.33%	2.53%	-1.45%	-0.07%	-0.04%
EBITDA+	-13.18M	-22.48M	-64.93M	-52.79M	-61.15M	-81.12M	124.45M	-54.17M	-58.71M	-61.27M
EBITDA Margin %	-	-	-	-	-	-6.43%	0.6%	-36.05%	-149.78%	-108.25%
EBITDA Growth %	-28.63%	-0.71%	-1.89%	0.19%	-0.16%	-0.33%	2.53%	-1.44%	-0.08%	-0.04%
D&A (Non-Cash Add-back)	11.78K	56.51K	80.31K	141.73K	255K	306.85K	237.08K	1.38M	568K	613K
EBIT	-13.19M	-22.54M	-64.81M	-52.93M	-61.41M	-81.43M	124.21M	-55.55M	-57.58M	-58.38M
Net Interest Income+	0	0	0	0	948.22K	395.4K	0	0	4.9M	3.9M
Interest Income	30.28K	0	201.51K	952.07K	948.22K	395.4K	0	0	4.9M	3.9M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	30.28K	120.82K	201.51K	952.07K	948.22K	395.4K	-45.69K	1.38M	6.94M	35.45M
Pretax Income+	-13.16M	-22.41M	-64.81M	-51.98M	-60.46M	-81.04M	124.16M	-54.17M	-52.34M	-26.43M
Pretax Margin %	-	-	-	-	-	-6.42%	0.6%	-36.05%	-133.52%	-46.7%
Income Tax+	0	-950	-80.31K	0	0	0	1.33M	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	0.99%	1%	1%	1%
Net Income+	-13.16M	-22.41M	-64.81M	-51.98M	-60.46M	-81.04M	122.83M	-54.17M	-52.34M	-26.43M
Net Margin %	-	-	-	-	-	-6.42%	0.59%	-36.05%	-133.52%	-46.7%
Net Income Growth %	-28.44%	-0.7%	-1.89%	0.2%	-0.16%	-0.34%	2.52%	-1.44%	0.03%	0.49%
Net Income (Continuing)	-13.16M	-22.41M	-64.81M	-51.98M	-60.46M	-81.04M	122.83M	-54.17M	-52.34M	-26.43M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.67	-1.14	-3.35	-2.11	-1.51	-1.39	1.76	-0.77	-0.74	-0.37
EPS Growth %	-6.13%	-0.7%	-1.94%	0.37%	0.28%	0.08%	2.27%	-1.44%	0.04%	0.5%
EPS (Basic)	-0.67	-1.14	-3.35	-2.11	-1.51	-1.39	1.78	-0.77	-0.74	-0.37
Diluted Shares Outstanding	19.6M	19.6M	19.34M	24.63M	39.22M	58.45M	68.07M	70.42M	70.58M	70.91M
Basic Shares Outstanding	19.6M	19.6M	19.34M	24.63M	39.22M	58.45M	67.48M	70.42M	70.58M	70.91M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	70.28M	52.41M	88.59M	44.27M	79.81M	74.84M	190.48M	131.38M	109.6M	55.94M
Cash & Short-Term Investments	69.94M	51.94M	87.13M	41.5M	76.74M	72.03M	187.8M	129M	105.83M	53.08M
Cash Only	69.94M	51.94M	87.13M	36.49M	41.9M	72.03M	187.8M	44.87M	27.04M	26.3M
Short-Term Investments	0	0	0	5.01M	34.84M	0	0	84.13M	78.79M	26.77M
Accounts Receivable	0	7.37K	0	0	1.13M	141.76K	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	4.1	-	-	-	-
Inventory	0	242.67K	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	58.64K	242.67K	0	600.1K	0	0	2.68M	1	1K	0
Total Non-Current Assets+	93.26K	616.68K	869.55K	3.38M	1.03M	1.08M	4.07M	23.89M	34.43M	36.23M
Property, Plant & Equipment	29.52K	43.59K	51.77K	69.87K	68.36K	135.62K	242.76K	16.07M	14.66M	13.23M
Fixed Asset Turnover	-	-	-	-	-	93.03x	858.40x	0.09x	0.03x	0.04x
Goodwill	0	0	0	0	-247	100	0	0	0	0
Intangible Assets	18.89K	110.07K	124.19K	391.87K	467.25K	318.9K	164K	222.1K	200K	92K
Long-Term Investments	0	0	0	0	0	0	3.56M	5.62M	17.63M	20.97M
Other Non-Current Assets	44.85K	463.01K	693.59K	2.92M	495.18K	627.8K	96.13K	1.97M	1.94M	1.93M
Total Assets+	70.38M	53.03M	89.46M	47.65M	80.84M	75.93M	194.54M	155.27M	144.03M	92.17M
Asset Turnover	-	-	-	-	-	0.17x	1.07x	0.01x	0.00x	0.01x
Asset Growth %	13.49%	-0.25%	0.69%	-0.47%	0.7%	-0.06%	1.56%	-0.2%	-0.07%	-0.36%
Total Current Liabilities+	2.31M	3.73M	6.02M	8.84M	10.53M	22.06M	14.8M	6.99M	11.47M	10.52M
Accounts Payable	670.54K	857.17K	2.03M	3.76M	3.26M	5.45M	7.13M	1.95M	3.7M	3.19M
Days Payables Outstanding	20.78K	-	9.21K	9.67K	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	1000K	0	0	0	0
Other Current Liabilities	0	0	2.08M	2.31M	4.55M	8.19M	3.91M	0	0	1K
Current Ratio	30.44x	14.04x	14.71x	5.01x	7.58x	3.39x	12.87x	18.79x	9.55x	5.32x
Quick Ratio	30.44x	13.97x	14.71x	5.01x	7.58x	3.39x	12.87x	18.79x	9.55x	5.32x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	286.56K	10.23M	0	16M	44.76M	13.42M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	16M	14.76M	13.42M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	286.56K	61.2K	0	1	30M	0
Total Liabilities	2.31M	3.73M	6.02M	8.84M	10.82M	32.29M	14.8M	22.99M	56.23M	23.94M
Total Debt+	0	0	0	0	0	0	0	16.54M	16M	14.76M
Net Debt	-69.94M	-51.94M	-87.13M	-36.49M	-41.9M	-72.03M	-187.8M	-28.33M	-11.04M	-11.55M
Debt / Equity	-	-	-	-	-	-	-	0.13x	0.18x	0.22x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-1.51x	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	68.07M	49.29M	83.44M	38.81M	70.02M	43.63M	179.75M	132.27M	87.8M	68.23M
Equity Growth %	13.37%	-0.28%	0.69%	-0.53%	0.8%	-0.38%	3.12%	-0.26%	-0.34%	-0.22%
Book Value per Share	3.47	2.51	4.31	1.58	1.79	0.75	2.64	1.88	1.24	0.96
Total Shareholders' Equity	68.07M	49.29M	83.44M	38.81M	70.02M	43.63M	179.75M	132.27M	87.8M	68.23M
Common Stock	21.15K	19.6K	24.61K	24.65K	54.71K	65.74K	70.36K	70.47K	71K	71K
Retained Earnings	-13.5M	-61.77M	-100.72M	-152.7M	-213.16M	-294.19M	-171.36M	-225.53M	-277.87M	-304.3M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-20.19K	-50.91K	-1.83K	2.47K	0	0	-42.19K	0	-35K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.49M	-17.8M	-31.47M	-45.56M	-51.09M	-51.58M	118.61M	-55.23M	-45.78M	-55.96M
Operating CF Margin %	-	-	-	-	-	-4.09%	0.57%	-36.75%	-116.79%	-98.86%
Operating CF Growth %	-19.99%	-2.25%	-0.77%	-0.45%	-0.12%	-0.01%	3.3%	-1.47%	0.17%	-0.22%
Net Income	-13.16M	-22.41M	-64.81M	-51.98M	-60.46M	-81.04M	119.84M	-54.17M	-52.34M	-26.43M
Depreciation & Amortization	11.78K	56.51K	80.31K	141.73K	255K	306.85K	237K	1.38M	1.6M	613K
Stock-Based Compensation	1.46M	3.64M	6.4M	7.06M	5.21M	7.53M	0	6.56M	7.29M	6.28M
Deferred Taxes	0	-3.64M	0	4.61K	0	0	0	0	0	0
Other Non-Cash Items	4.39M	3.64M	25.86M	-1.24K	-29.63K	-199.41K	15.35M	-764.94K	-4.71M	-36.26M
Working Capital Changes	1.81M	914.4K	996.85K	-787.91K	3.94M	21.82M	-16.81M	-8.23M	2.39M	-150K
Change in Receivables	-69.22K	50.26K	7.37K	0	-531.04K	989.38K	141.76K	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	591.41K	186.62K	1.08M	1.65M	-653.95K	2.33M	1.7M	-5.17M	1.75M	-512K
Cash from Investing+	-56.33K	-188.99K	-47.39K	-5.36M	-30.04M	34.65M	-1.82M	-87.88M	-2.58M	54.59M
Capital Expenditures	-56.33K	-188.99K	-47.39K	-352.02K	-57.16K	-127.24K	-189.41K	-1.42M	-40.31K	-71K
CapEx % of Revenue	-	-	-	-	-	0.01%	0%	0.94%	0.1%	0.13%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-24.25K	-158.62K	-8.48K	-318.15K	-186.89K	-263.44K	0	-1M	-97.15K	-89K
Cash from Financing+	70.64M	-13.67K	66.7M	286.14K	86.54M	47.07M	904.08K	180.66K	30.54M	622K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-13.67K	-3.05M	286.14K	131.9K	341.04K	-21.31K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.54M	-17.99M	-31.52M	-45.91M	-51.33M	-51.97M	118.43M	-56.65M	-45.92M	-56.03M
FCF Margin %	-	-	-	-	-	-4.12%	0.57%	-37.69%	-117.14%	-98.99%
FCF Growth %	-20.07%	-2.25%	-0.75%	-0.46%	-0.12%	-0.01%	3.28%	-1.48%	0.19%	-0.22%
FCF per Share	-0.28	-0.92	-1.63	-1.86	-1.31	-0.89	1.74	-0.80	-0.65	-0.79
FCF Conversion (FCF/Net Income)	0.42x	0.79x	0.49x	0.88x	0.85x	0.64x	0.97x	1.02x	0.87x	2.12x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-36.15%	-38.2%	-97.65%	-85.04%	-111.11%	-142.6%	109.98%	-34.72%	-47.57%	-33.88%
Return on Invested Capital (ROIC)	-	-	-	-	-302.59%	-	-	-86.89%	-49.21%	-69.57%
Gross Margin	-	-	-	-	-	100%	100%	100%	100%	100%
Net Margin	-	-	-	-	-	-642.26%	58.95%	-3604.66%	-13351.79%	-4670.14%
Debt / Equity	-	-	-	-	-	-	-	0.13x	0.18x	0.22x
FCF Conversion	0.42x	0.79x	0.49x	0.88x	0.85x	0.64x	0.97x	1.02x	0.87x	2.12x
Revenue Growth	-	-	-	-	-	-	1551.57%	-99.28%	-73.91%	44.39%

Revenue by Segment

	2021	2022
License	12.38M	1.5M
License Growth	-	-87.86%
Related Party	196M	-
Related Party Growth	-	-

Frequently Asked Questions

Growth & Financials

Ovid Therapeutics Inc. (OVID) reported $6.6M in revenue for fiscal year 2024.

Ovid Therapeutics Inc. (OVID) grew revenue by 44.4% over the past year. This is strong growth.

Ovid Therapeutics Inc. (OVID) reported a net loss of $36.3M for fiscal year 2024.

Dividend & Returns

Ovid Therapeutics Inc. (OVID) has a return on equity (ROE) of -33.9%. Negative ROE indicates the company is unprofitable.

Ovid Therapeutics Inc. (OVID) had negative free cash flow of $38.0M in fiscal year 2024, likely due to heavy capital investments.